Quick Answer
enGene Therapeutics Inc. reported Stockholders Equity of $167.71 million for the year ending 2025.
- enGene Therapeutics Inc. showed a decrease of -38.5% in Stockholders Equity from 2024 to 2025.
- This data is from enGene Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on December 22, 2025.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$84.01 million | Q2 2023: -$89.24 million | Q3 2023: -$93.92 million | Q1 2024: $62.39 million | Q2 2024: $242.97 million | Q3 2024: $230.33 million | Q4 2024: $272.61 million | Q1 2025: $249.95 million | Q2 2025: $227.29 million | Q3 2025: $200.67 million | Q4 2025: $167.71 million | Q1 2026: $281.55 million.
- Over the full 5 years of available data (2021 to 2025), enGene Therapeutics Inc.'s Stockholders Equity has grown by 413.8%.
- Historical annual values: Fiscal year 2025: $167.71 million | Fiscal year 2024: $272.61 million | Fiscal year 2023: $72.49 million | Fiscal year 2022: -$76.61 million | Fiscal year 2021: -$53.44 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: